Technical Analysis for PSTI - Pluristem Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 9.0 0.33% 0.03
PSTI closed up 0.33 percent on Monday, August 10, 2020, on 1.12 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical PSTI trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 0.33%
MACD Bearish Signal Line Cross Bearish 0.33%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.33%
Calm After Storm Range Contraction 0.33%
NR7 Range Contraction 0.33%
Down 3 Days in a Row Weakness 0.33%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pluristem Therapeutics Inc., a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases. The company's products are derived from human placenta that is a non-controversial, non-embryonic, and adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company develops placenta expanded cells (PLX) and peripheral artery disease cells, an allogeneic therapeutic product that is in Phase-II clinical trials for the treatment of intermittent claudication, critical limb ischemia, and Buerger's disease. Its PLX product is developed for the treatment of muscle injury, bone marrow diseases, inflammatory bowel disease, and multiple sclerosis, as well as for pulmonary disorders, acute radiation syndrome, acute myocardial infarction, diabetic diastolic heart failure, neuropathic pain, inflammatory bowel disease, multiple sclerosis, and ischemic stroke for which the product is in various pre-clinical trials. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.
Biotechnology Life Sciences Biology Diseases Pain Stem Cells Radiation Multiple Sclerosis Inflammatory Bowel Disease Pulmonary Arterial Hypertension Cell Therapy Peripheral Artery Disease Acute Myocardial Infarction

Is PSTI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.29
52 Week Low 2.82
Average Volume 591,680
200-Day Moving Average 5.84
50-Day Moving Average 8.52
20-Day Moving Average 9.15
10-Day Moving Average 9.46
Average True Range 0.83
ADX 22.05
+DI 27.77
-DI 17.35
Chandelier Exit (Long, 3 ATRs ) 9.67
Chandelier Exit (Short, 3 ATRs ) 10.34
Upper Bollinger Band 10.42
Lower Bollinger Band 7.88
Percent B (%b) 0.44
BandWidth 27.75
MACD Line 0.23
MACD Signal Line 0.27
MACD Histogram -0.0434
Fundamentals Value
Market Cap 877.25 Million
Num Shares 97.5 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -28.13
Price-to-Sales 0.00
Price-to-Book 6.15
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.02
Resistance 3 (R3) 10.07 9.78 9.85
Resistance 2 (R2) 9.78 9.52 9.76 9.79
Resistance 1 (R1) 9.39 9.36 9.25 9.34 9.74
Pivot Point 9.10 9.10 9.03 9.08 9.10
Support 1 (S1) 8.71 8.84 8.57 8.66 8.26
Support 2 (S2) 8.42 8.68 8.40 8.21
Support 3 (S3) 8.03 8.42 8.15
Support 4 (S4) 7.98